2 interactions on record
Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of VFEND.
Source: FDA drug label - voriconazole
7 DRUG INTERACTIONS CYP3A4 Inhibitors : Consider dose reduction of sunitinib malate when administered with strong CYP3A4 inhibitors. ( 7.1 ) CYP3A4 Inducers : Consider dose increase of sunitinib malate when administered with strong CYP3A4 inducers. ( 7.1 ) 7.1 Effect of Other Drugs on Sunitinib Malate Strong CYP3A4 Inhibitors Co-administration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [see Clinical Pharmacology ( 12.3 )] .
Source: FDA drug label - sunitinib malate